Comparative Pharmacology
Head-to-head clinical analysis: VIGPODER versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGPODER versus XCOPRI.
VIGPODER vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
150 mg orally twice daily with or without food.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category C
Category C
Anticonvulsant
Anticonvulsant